Research · United States
Nature: Cobenfy is the first schizophrenia drug with a new mechanism in over 70 years
A Nature commentary places the muscarinic-agonist approval in the long arc of antipsychotic pharmacology.
Nature's commentary on the Cobenfy approval situates it inside the seventy-plus-year history of antipsychotic development. The first generation worked on dopamine D2 receptors. The second generation tweaked that profile. Cobenfy is the first to step entirely off dopamine and onto M1/M4 muscarinic receptors.
The piece is candid about the unknowns — durability, long-term tolerability, and what the drug means for negative and cognitive symptoms — but treats the approval as the most genuinely new mechanism the field has had in a generation.
Read the Nature commentary for the pharmacological context and outstanding questions.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.
If reading this brought something up for you —
Call or text 988 for the Suicide & Crisis Lifeline. See all crisis resources.